Inaticabtagene autoleucel is under clinical development by Juventas Cell Therapy and currently in Phase I for Acquired (Autoimmune) Hemolytic Anemia. According to GlobalData, Phase I drugs for Acquired (Autoimmune) Hemolytic Anemia have a 95% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Inaticabtagene autoleucel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Go deeper with GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Inaticabtagene autoleucel overview
Inaticabtagene Autoleucel (CNCT 19) is a CD19 CAR-T cell therapy product. It is formulated as a solution for intravenous route of administration. Inaticabtagene Autoleucel is indicated for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
Inaticabtagene Autoleucel is under development for the treatment of relapsed or refractory diffuse large B cell lymphoma, follicular lymphoma (FL), transformed large B-cell lymphoma, B-cell acute lymphoblastic leukemia (B-ALL), relapsed and refractory acute lymphoblastic leukemia, non-Hodgkin lymphoma (NHL), hepatocellular carcinoma, lupus nephritis, immune thrombocytopenia, acquired (autoimmune) hemolytic anemia , ANCA-associated vasculitis and dermatomyositis. The therapeutic candidate consists of T cells engineered to express chimeric antigen receptors (CAR T-cells). It acts by targeting CD19 expressing cancer cells. The therapeutic candidate is administered through intravenous infusion.
It was also under development for the treatment of chronic lymphocytic leukemia (CLL).
Juventas Cell Therapy overview
Juventas Cell Therapy (Juventas) is a biotechnology company that develops immune cell therapeutic drugs. Juventas is headquartered in Beijing, China.
For a complete picture of Inaticabtagene autoleucel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
